BridgeBio Pharma (NASDAQ:BBIO) Trading 0.3% Higher

BridgeBio Pharma (NASDAQ:BBIO)’s stock price traded up 0.3% on Tuesday . The company traded as high as $31.60 and last traded at $31.23, 6,627 shares changed hands during trading. A decline of 97% from the average session volume of 236,952 shares. The stock had previously closed at $31.14.

BBIO has been the subject of several research reports. UBS Group began coverage on shares of BridgeBio Pharma in a report on Tuesday. They issued a “reduce” rating for the company. Piper Jaffray Companies dropped coverage on BridgeBio Pharma in a research note on Friday, October 18th. Finally, Zacks Investment Research upgraded BridgeBio Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. BridgeBio Pharma has an average rating of “Buy” and an average target price of $40.13.

The company has a quick ratio of 14.00, a current ratio of 14.00 and a debt-to-equity ratio of 0.14. The firm has a fifty day simple moving average of $24.73.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Thursday, November 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.04. The business had revenue of $26.74 million for the quarter. As a group, research analysts predict that BridgeBio Pharma will post -3.08 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in BridgeBio Pharma during the second quarter worth $476,000. Janus Henderson Group PLC purchased a new position in shares of BridgeBio Pharma in the second quarter valued at $9,331,000. TimesSquare Capital Management LLC purchased a new stake in BridgeBio Pharma during the 2nd quarter worth $4,046,000. JPMorgan Chase & Co. acquired a new position in BridgeBio Pharma in the 2nd quarter worth $25,274,000. Finally, Monashee Investment Management LLC purchased a new position in BridgeBio Pharma in the 2nd quarter valued at about $1,349,000. 83.46% of the stock is owned by institutional investors and hedge funds.

About BridgeBio Pharma (NASDAQ:BBIO)

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Further Reading: What is total return in investing?

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit